And Schafmeister isn’t the only chemist turning to modular methods of synthesis to explore vast regions of chemical space. It ...

A University at Buffalo-led team of researchers has developed a method for producing advanced nanoparticles that could ...

A new theory suggests many age-related diseases may actually start decades before symptoms appear. Researchers say early-life damage — from infections, injuries, or genetic mutations — can remain ...

Fives ProSim, a subsidiary of the Fives Group and an expert in industrial process simulation and optimization, announces the release of ProSimPlus Python API. This new solution enables users to run ...

NEW YORK — Federal prosecutors have charged two men with using artificial intelligence to create nude videos and photos of female celebrities under a newly enacted law meant to halt the spread of ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. OpenAI wants you to know how good its latest image generator is —and it has a few fake screenshots and ...

OpenAI (OPENAI) introduced ChatGPT Images 2.0 on Tuesday, which improves on the quality of the images, reduces the error rate, and allows users to generate multiple ...

Imtiaz Tyab is a CBS News senior foreign correspondent based in London and reports for all platforms, including the "CBS Evening News," "CBS Mornings," "CBS Sunday Morning" and CBS News 24/7. He has ...

The co-founder of Super Micro Computer and two others were charged with diverting $2.5 billion worth of servers with Nvidia’s artificial intelligence chips to China, in violation of US laws barring ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...